NASDAQ:SRRK

Scholar Rock Competitors

$30.77
-0.13 (-0.42 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$29.92
Now: $30.77
$31.54
50-Day Range
$27.84
MA: $50.87
$68.02
52-Week Range
$10.28
Now: $30.77
$70.00
Volume282,468 shs
Average Volume302,323 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.35

Competitors

Scholar Rock (NASDAQ:SRRK) Vs. SWTX, NSTG, RVMD, RLAY, VCEL, and EDIT

Should you be buying SRRK stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Scholar Rock, including SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Revolution Medicines (RVMD), Relay Therapeutics (RLAY), Vericel (VCEL), and Editas Medicine (EDIT).

SpringWorks Therapeutics (NASDAQ:SWTX) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

SpringWorks Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Earnings & Valuation

This table compares SpringWorks Therapeutics and Scholar Rock's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.72
Scholar Rock$20.49 million51.45$-51,000,000.00($1.85)-16.63

Scholar Rock has higher revenue and earnings than SpringWorks Therapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for SpringWorks Therapeutics and Scholar Rock, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SpringWorks Therapeutics00403.00
Scholar Rock00503.00

SpringWorks Therapeutics currently has a consensus price target of $95.20, suggesting a potential upside of 33.26%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 100.13%. Given Scholar Rock's higher probable upside, analysts clearly believe Scholar Rock is more favorable than SpringWorks Therapeutics.

Profitability

This table compares SpringWorks Therapeutics and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SpringWorks TherapeuticsN/A-24.48%-23.58%
Scholar Rock-365.84%-80.16%-41.33%

Insider and Institutional Ownership

76.3% of SpringWorks Therapeutics shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 51.2% of SpringWorks Therapeutics shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

NanoString Technologies (NASDAQ:NSTG) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Volatility and Risk

NanoString Technologies has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Insider and Institutional Ownership

98.3% of NanoString Technologies shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 4.2% of NanoString Technologies shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares NanoString Technologies and Scholar Rock's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NanoString Technologies$125.57 million25.92$-40,700,000.00($1.93)-37.83
Scholar Rock$20.49 million51.45$-51,000,000.00($1.85)-16.63

NanoString Technologies has higher revenue and earnings than Scholar Rock. NanoString Technologies is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NanoString Technologies and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NanoString Technologies-53.47%-68.96%-24.15%
Scholar Rock-365.84%-80.16%-41.33%

Analyst Recommendations

This is a summary of current recommendations and price targets for NanoString Technologies and Scholar Rock, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NanoString Technologies01402.80
Scholar Rock00503.00

NanoString Technologies currently has a consensus price target of $68.60, suggesting a potential downside of 6.04%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 100.13%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than NanoString Technologies.

Revolution Medicines (NASDAQ:RVMD) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

85.8% of Revolution Medicines shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Revolution Medicines and Scholar Rock's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$50.04 million59.13$-47,660,000.00N/AN/A
Scholar Rock$20.49 million51.45$-51,000,000.00($1.85)-16.63

Revolution Medicines has higher revenue and earnings than Scholar Rock.

Profitability

This table compares Revolution Medicines and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Revolution Medicines-191.17%-32.25%-20.55%
Scholar Rock-365.84%-80.16%-41.33%

Analyst Ratings

This is a breakdown of current ratings and target prices for Revolution Medicines and Scholar Rock, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Revolution Medicines00203.00
Scholar Rock00503.00

Revolution Medicines currently has a consensus price target of $51.00, suggesting a potential upside of 26.49%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 100.13%. Given Scholar Rock's higher probable upside, analysts plainly believe Scholar Rock is more favorable than Revolution Medicines.

Summary

Revolution Medicines beats Scholar Rock on 7 of the 10 factors compared between the two stocks.

Relay Therapeutics (NASDAQ:RLAY) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Insider & Institutional Ownership

98.4% of Relay Therapeutics shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Relay Therapeutics and Scholar Rock's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relay TherapeuticsN/AN/AN/AN/AN/A
Scholar Rock$20.49 million51.45$-51,000,000.00($1.85)-16.63

Relay Therapeutics has higher earnings, but lower revenue than Scholar Rock.

Profitability

This table compares Relay Therapeutics and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Relay TherapeuticsN/AN/AN/A
Scholar Rock-365.84%-80.16%-41.33%

Analyst Ratings

This is a breakdown of current ratings and target prices for Relay Therapeutics and Scholar Rock, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Relay Therapeutics01502.83
Scholar Rock00503.00

Relay Therapeutics currently has a consensus price target of $57.40, suggesting a potential upside of 77.22%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 100.13%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Relay Therapeutics.

Vericel (NASDAQ:VCEL) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Vericel has a beta of 3.11, suggesting that its stock price is 211% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Insider & Institutional Ownership

93.1% of Vericel shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 4.3% of Vericel shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Vericel and Scholar Rock's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vericel$117.85 million22.93$-9,660,000.00$0.18325.67
Scholar Rock$20.49 million51.45$-51,000,000.00($1.85)-16.63

Vericel has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vericel and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vericel0.12%0.13%0.10%
Scholar Rock-365.84%-80.16%-41.33%

Analyst Ratings

This is a breakdown of current ratings and target prices for Vericel and Scholar Rock, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vericel02602.75
Scholar Rock00503.00

Vericel currently has a consensus price target of $49.00, suggesting a potential downside of 15.00%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 100.13%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Vericel.

Summary

Vericel beats Scholar Rock on 9 of the 14 factors compared between the two stocks.

Editas Medicine (NASDAQ:EDIT) and Scholar Rock (NASDAQ:SRRK) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Volatility and Risk

Editas Medicine has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500.

Profitability

This table compares Editas Medicine and Scholar Rock's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Editas Medicine-99.62%-26.74%-16.38%
Scholar Rock-365.84%-80.16%-41.33%

Analyst Ratings

This is a breakdown of current ratings and target prices for Editas Medicine and Scholar Rock, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Editas Medicine44402.00
Scholar Rock00503.00

Editas Medicine currently has a consensus price target of $47.3636, suggesting a potential upside of 33.98%. Scholar Rock has a consensus price target of $61.60, suggesting a potential upside of 100.13%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Editas Medicine.

Insider & Institutional Ownership

87.5% of Editas Medicine shares are held by institutional investors. Comparatively, 61.9% of Scholar Rock shares are held by institutional investors. 0.9% of Editas Medicine shares are held by insiders. Comparatively, 24.6% of Scholar Rock shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Editas Medicine and Scholar Rock's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$20.53 million113.76$-133,750,000.00($2.68)-12.94
Scholar Rock$20.49 million51.45$-51,000,000.00($1.85)-16.63

Scholar Rock has lower revenue, but higher earnings than Editas Medicine. Scholar Rock is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.


Scholar Rock Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$70.01-5.1%$3.43 billionN/A-40.24Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.01-1.6%$3.25 billion$125.57 million-42.70Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32-3.1%$2.96 billion$50.04 million0.00
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.60-3.5%$2.95 billionN/A0.00News Coverage
Vericel logo
VCEL
Vericel
1.1$58.62-1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.67-18.2%$2.34 billion$20.53 million-19.93Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.49-0.7%$2.10 billion$31.43 million-5.13Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$24.30-1.0%$1.97 billionN/A-11.36Decrease in Short Interest
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.28-5.1%$1.90 billion$44.67 million-2.58
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.66-0.3%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33-0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Immunovant logo
IMVT
Immunovant
1.8$15.42-3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
REGENXBIO logo
RGNX
REGENXBIO
1.6$34.51-3.9%$1.47 billion$35.23 million-13.92Increase in Short Interest
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
AlloVir logo
ALVR
AlloVir
1.4$22.08-2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.55-1.1%$1.40 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.65-10.4%$1.21 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22-7.0%$935.20 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86-2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01-6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$15.88-8.3%$854.84 millionN/A0.00Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.40-0.5%$829.93 million$22.99 million-10.32
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25-3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
Inhibrx logo
INBX
Inhibrx
1.6$18.03-16.4%$680.60 millionN/A0.00Decrease in Short Interest
Gap Up
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.04-3.5%$663.63 million$14.75 million-2.59Increase in Short Interest
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00-1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.35-1.5%$630.05 million$9.86 million-9.07
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.08-1.6%$623.24 million$13.29 million-9.99
Athira Pharma logo
ATHA
Athira Pharma
2.1$16.59-0.8%$615.82 millionN/A0.00Analyst Downgrade
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.61-7.1%$586.59 millionN/A0.00Lockup Expiration
Gap Down
Compugen logo
CGEN
Compugen
1.4$8.57-3.9%$586.36 million$17.80 million-23.16Analyst Report
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.04-2.6%$538.67 millionN/A-2.45Increase in Short Interest
Agenus logo
AGEN
Agenus
1.6$2.62-1.5%$536.28 million$150.05 million-2.40
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.